Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...
The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...
Investor's Business Daily on MSN8h
Stock Market Today: Chevron Breaks Out, But Biotechs Struggle As Eli Lilly Looks Like Short-Sale Play (Live Coverage)Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...
Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback